TGFBR1 and breast carcinoma: Early meta-analyses by ref. 44 and ref. 32 that analyzed up to 12 case-control studies (4871 subjects) found an association of TGFBR1*6A with breast cancer risk with odds ratios of 1.48 (95% CI 1.11–1.96) and 1.38 (95% CI 1.14–1.67), respectively.